
**Tools for Practice** is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,500 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research. <u>www.acfp.ca</u>

August 14, 2017



Riboflavin for Migraine Prophylaxis: Something "2-B" excited about?

Clinical Question: Does daily riboflavin (vitamin B<sub>2</sub>) prevent migraines?

Bottom-line: Studies of riboflavin are inconsistent and often have high placebo response rates. Most randomized, controlled trials (RCTs) found no reduction in migraine frequency. One study found for every three adults treated with riboflavin, one patient would have  $a \ge 50\%$  reduction in migraine frequency compared to placebo. Adverse effects are poorly reported, but include diarrhea and discoloured urine.

# Evidence:

- Adults:
  - Three double-blind randomized controlled trials (RCTs), younger, predominantly female, Western Europe/US. All outcomes reported at three months.
    - 55 patients, ~4 migraines/month, randomized to riboflavin 400 mg daily or placebo (with ß-carotene).<sup>1</sup>
      - ≥ 50% reduction in frequency: 56% versus 19% (placebo); Number Needed to Treat (NNT)=3.
      - Limitations: Inconsistent statistical applications, origin of funding unclear, limited adverse event reporting.
    - 112 patients, six days of migraine/month, randomized to nutritional product with riboflavin 400 mg, Magnesium/Coenzyme Q<sub>10</sub> and other vitamins or indistinguishable placebo divided twice daily.<sup>2</sup>
      - Both reduced days of migraine/month 1.8 versus 1.3 (placebo). Not statistically significant (NSS).
        - No meaningful differences in other outcomes.
      - More adverse effects with riboflavin (mostly diarrhea or discoloured urine): Number Needed to Harm (NNH)=4.
      - Limitations: Unclear randomization concealment (with more in placebo having co-morbidities).
    - 49 patients: Riboflavin 400 mg with magnesium/feverfew or "placebo" (riboflavin 25 mg).<sup>3</sup>

- ≥50% reduction in frequency 42% versus 44% (placebo); NSS.
- Fewer monthly migraines: 1.8 versus 1.7 (placebo); NSS.
- Limitations: Unclear randomization concealment, possible active comparator, no adverse effects reported.
- Pediatrics:
  - Two placebo-controlled RCTs (Australia/Netherlands) riboflavin 50 mg versus placebo (with carotene) (42 children)<sup>4</sup> and 200 mg versus identical placebo (48 children):<sup>5</sup>
    - No difference in days with migraine or headache intensity.<sup>4,5</sup>
    - ≥50% reduction in frequency: 44% versus 67% (placebo); NSS.<sup>5</sup>
    - Limitations: Underpowered<sup>5</sup>
  - Third study uninterpretable due to significant differences in baseline characteristics.<sup>6</sup>
- Systematic reviews did not complete meta-analyses (so we focused on RCTs above).<sup>7-10</sup>

## Context:

- Prophylaxis is recommended for those with  $\geq$ 3 moderate-severe headaches/month.<sup>7</sup>
  - The best evidence for migraine prophylaxis supports propranolol and amitriptyline, which benefit 1 in 4 and 1 in 8 patients over placebo, respectively.<sup>11,12</sup>
- Guidelines "strongly recommend" riboflavin (based on low quality evidence)<sup>7</sup> or suggest riboflavin probably effective<sup>8</sup> in adults.

### Authors:

Evan Sehn BScPharm PharmD Candidate, Michael R Kolber BSc MD CCFP MSc, Adrienne J Lindblad BSP PharmD ACPR

### Disclosure:

Authors do not have any conflicts of interest to declare.

### References:

- 1. Schoenen J, Jacquy J, Lenaerts M. Neurology. 1998; 50(2):466-70.
- 2. Gaul C, Diener H-C, Danesch U. J Headache Pain. 2015; 16(32):1-8.
- 3. Maizels M, Blumenfeld A, Burchette R. Headache. 2004; 44(9):885-90.
- 4. Bruijn J, Duivenvoorden H, Passchier J, et al. Cephalalgia. 2010; 30(12):1426-34.
- 5. MacLennan S, Wade F, Forrest KM, et al. J Child Neurol. 2008; 23(11):1300-4.
- 6. Athaillah, Dimyati Y, Saing JH, et al. Paediatr Indones. 2012; 52(3):132-7.
- 7. Pringsheim T, Davenport WJ, Mackie G, *et al.* Can J Neurol Sci. 2012; 39(2): Supplement 2.
- 8. Holland S, Silberstein SD, Freitag F, et al. Neurology. 2012; 78:1346-53.
- 9. Orr SL, Venkateswaran S. Cephalalgia. 2014; 34(8):568-83.
- 10. Namazi N, Heshmati J, Tarighat-Esfanjani A. Int J Vitam Nutr Res. 2015; 85(1-2):79-87.
- 11. Kapusta MJ, Allan GMA. Tools for Practice. Available at: <u>https://www.acfp.ca/wp-content/uploads/tools-for-practice/1433184708\_updatedtfp52antihypertensivesmigraineprophylaxis.pdf</u>. Last Accessed: March 22, 2017.
- 12. Allan GMA, Levy M. Tools for Practice. Available at: <u>https://www.acfp.ca/wp-content/uploads/tools-for-practice/1433184684\_updatedtfp51antidepressantsheadaches.pdf</u>. Last Accessed: March 22, 2017.

**Tools for Practice** is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practising family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic integrity. If you are not a member of the ACFP and would like to receive the TFP emails, please sign up for the distribution list at <a href="http://bit.ly/signupfortfps">http://bit.ly/signupfortfps</a>. Archived articles are available on the ACFP website.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.